Skip to content
← Pituitary Tumors

HEALTH PROFESSIONAL · SOURCE READING

Treatment Options for Adrenocorticotropic Hormone (ACTH)–Producing Pituitary Tumors

Source: Pituitary Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 17, 2024 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Adrenocorticotropic Hormone–Producing Pituitary Tumors

Treatment options for ACTH-producing pituitary tumors include:

Surgery (usually a transsphenoidal approach).[1-3]

Source links and citations

Surgery plus radiation therapy.[1,2,4]

Source links and citations

Radiation therapy.[1,2,4]

Source links and citations

Steroidogenesis inhibitors, including mitotane, metyrapone, ketoconazole, and aminoglutethimide.[1,2,5]

Source links and citations

Stereotactic radiation surgery (under clinical evaluation).[4,6,7]

Source links and citations

Transsphenoidal microsurgery is the treatment of choice for patients with corticotroph adenomas.[1,2] Most series report remission rates of approximately 70% to 90%.[1] In a series of 216 patients who underwent surgery using a transsphenoidal approach, 75% experienced long-term remission, 21% experienced persistence of Cushing disease, and 9% had recurrence after the initial correction of the hypercortisolism.[3] The average time interval for reoperation was 3.8 years. Seventy-nine percent of the tumors were microadenomas, and 18% were macroadenomas; 86% of the cases with microadenoma had long-term remission, compared with only 46% of those with macroadenoma. In cases in which hypercortisolemia persists, early repeat exploration and/or radiation therapy or laparoscopic bilateral adrenalectomy may be required.[2]

Source links and citations

Radiation therapy has been used in patients who are not surgical candidates and has also been used as adjuvant therapy in patients with residual or recurrent active tumor.[1,4]

Source links and citations

Drug therapy may be an adjunct to transsphenoidal microsurgery in cases of residual tumor and in cases where radiation therapy has a delayed effect.[1] Steroidogenesis inhibitors, including mitotane, metyrapone, ketoconazole, and aminoglutethimide are used. Ketoconazole is the best tolerated of these agents and is effective as monotherapy in about 70% of patients.[5]

Source links and citations

If untreated, patients frequently die of cardiovascular disease or infection.

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice